11/04/2024 | Press release | Distributed by Public on 11/04/2024 16:08
Delaware
|
11-3516358
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification Number.)
|
37000 Grand River Avenue, Suite 120
Farmington Hills, MI
|
48335
|
|
(Address of principal executive offices)
|
(Zip code)
|
Ocuphire Pharma, Inc. 2021 Inducement Plan
|
(Full title of the plan)
|
Dr. George Magrath
Chief Executive Officer
Opus Genetics, Inc.
37000 Grand River Avenue, Suite 120
Farmington Hills, MI 48335
(248) 957-9024
|
(Name, address, and telephone number, including area code, of agent for service)
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☒
|
Smaller reporting company ☒
|
Emerging growth company ☐
|
Item 3.
|
Incorporation of Documents By Reference.
|
(a)
|
the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on March 8, 2024;
|
(b)
|
the Registrant's Quarterly Reports on Form 10-Q, filed with the Commission on May 10, 2024 and August 13, 2024;
|
(c)
|
the Registrant's Current Reports on Form 8-K, filed with the Commission on February 16, 2024, April 17, 2024, June 13, 2024, and October 22, 2024; and
|
(d)
|
the description of the Registrant's Common Stock contained in the Registrant's Form 8-A (File No. 001-34079), as filed with the Commission pursuant to Sections 12(b) and 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), on June 7, 2019, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.11 to the Registrant's Annual Report on Form 10-K, filed with the Commission on March 11, 2021.
|
Item 8. |
Exhibits.
|
Exhibit
Number
|
Description
|
|
Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q, filed with the Commission on August 13, 2024).
|
||
Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K, filed with the Commission on October 22, 2024).
|
||
Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 to the Registrant's Current Report on Form 8-K, filed with the Commission on October 22, 2024).
|
||
Ocuphire Pharma, Inc. 2021 Inducement Plan (incorporated by reference to Exhibit 10.41 to the Registrant's Annual Report on Form 10-K, filed with the Commission on March 11, 2021).
|
||
First Amendment to Ocuphire Pharma, Inc. 2021 Inducement Plan (incorporated by reference to Exhibit 10.3 to the Registrant's Current Report on Form 8-K, filed with the Commission on November 1, 2023).
|
||
4.6*
|
Second Amendment to Ocuphire Pharma, Inc. 2021 Inducement Plan.
|
|
5.1*
|
Opinion of Sidley Austin LLP.
|
|
23.1*
|
Consent of Ernst & Young LLP.
|
|
23.2*
|
Consent of Sidley Austin LLP (included in Exhibit 5.1).
|
|
24.1*
|
Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement).
|
|
107*
|
Filing Fee Table.
|
OPUS GENETICS, INC.
|
||
By:
|
/s/ Dr. George Magrath
|
|
Name:
|
Dr. George Magrath
|
|
Title:
|
Chief Executive Officer
|
SIGNATURE
|
TITLE
|
DATE
|
||
/s/ Dr. George Magrath
|
||||
Dr. George Magrath
|
Chief Executive Officer & Director
(Principal Executive Officer)
|
November 4, 2024
|
||
/s/ Nirav Jhaveri
|
||||
Nirav Jhaveri
|
Chief Financial Officer
(Principal Financial Officer)
|
November 4, 2024
|
||
/s/ Amy Rabourn
|
||||
Amy Rabourn
|
Senior Vice President of Finance
(Principal Accounting Officer)
|
November 4, 2024
|
||
/s/ Cam Gallagher
|
||||
Cam Gallagher
|
Chair of the Board
|
November 4, 2024
|
||
/s/ Sean Ainsworth
|
||||
Sean Ainsworth
|
Director
|
November 4, 2024
|
||
/s/ Dr. Jean Bennett
|
||||
Dr. Jean Bennett
|
Director
|
November 4, 2024
|
||
/s/ Susan K. Benton
|
||||
Susan K. Benton
|
Director
|
November 4, 2024
|
||
/s/ Dr. Adrienne Graves
|
||||
Dr. Adrienne Graves
|
Director
|
November 4, 2024
|
||
/s/ James S. Manuso
|
||||
James S. Manuso
|
Director
|
November 4, 2024
|
||
/s/ Richard J. Rodgers
|
||||
Richard J. Rodgers
|
Director
|
November 4, 2024
|
||
/s/ Dr. Benjamin R. Yerxa
|
||||
Dr. Benjamin R. Yerxa
|
President and Director
|
November 4, 2024
|